Q-omics provides the consensus-scored OCSTAMP profile across patient tissues and cancer cell-line models. OCSTAMP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, OCSTAMP is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, OCSTAMP RNA expression shows 6,975 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, THCA, and STAD as cancer lineages where OCSTAMP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OCSTAMP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OCSTAMP survival associations across molecular data types. OCSTAMP RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OCSTAMP RNA expression–survival associations across cancer types. High OCSTAMP expression shows unfavorable associations in LGG, KIRP and BRCA, but favorable associations in COAD, SKCM and SCLC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for OCSTAMP RNA expression.
This table summarizes OCSTAMP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for OCSTAMP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OCSTAMP shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in THCA, STAD and LUSC. The THCA box plot shows higher OCSTAMP RNA expression in tumor versus normal tissue (log2 FC = +0.170, t-test p < 0.001).
This table shows molecular features associated with OCSTAMP in patient tissues and cancer cell lines. In patient samples, OCSTAMP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OCSTAMP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
